Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03482102
Title Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

biliary tract cancer

hepatocellular carcinoma

Therapies

Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.